Skip to main content
. 2022 Dec 5;10(5):1779–1782. doi: 10.1016/j.gendis.2022.11.002

Figure 1.

Fig. 1

Inhibition of LSD1 suppresses tumor growth and metastasis by downregulating PD-L1 expression in lung adenocarcinoma. (A) Expression of E-cadherin, PD-L1, and H3K4me2 in cells treated with 10 μM GSK for 4 days. (B) Expression of E-cadherin and N-cadherin in cells treated with GSK for 4 days. (C) The cellular clone formation ability in cells treated with GSK. (D) The scratch healing ability in cells treated with GSK. (E) Expression of PD-L1 in cells treated with GSK or 10 ng/mL IFN-γ for 4 days. (F) Expression of PD-L1 and LSD1 in NCI–H1975 cells infected with LSD1-specific siRNA and the corresponding negative control. (G) Expression of PD-L1, E-cadherin, and N-cadherin. (H) the scratch healing ability and (I) the cellular clone formation ability in NCI–H1975 cells transfected with sh-NC and sh-PD-L1. (J) Expression of PD-L1 and E-cadherin, and (K) scratch healing ability in NCI–H1975 cells transfected with sh-NC or sh-PD-L1 and treated with 10 μM GSK. (L) Tumor volume. (M) Expression of PD-L1 and E-cadherin in the tumor. (N) Enhanced bioluminescence imaging of mice on day 0, day 10, day 20, and day 30 after GSK injection. (O) Lung metastatic nodules. ∗P < 0.05, ∗∗P < 0.01.